Pulmonary tuberculosis: Evaluation of current diagnostic strategy.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
May 2021
Historique:
received: 12 10 2019
revised: 21 04 2020
accepted: 08 10 2020
pubmed: 19 10 2020
medline: 27 8 2021
entrez: 18 10 2020
Statut: ppublish

Résumé

To identify tools that will result in faster diagnosis, making the current pulmonary tuberculosis strategy more efficient. A 4-year (2015-2018) retrospective study. The gold standard for diagnosis was a positive culture from a respiratory specimen. All sputum, fibroscopy and post-fibroscopy specimens (for smear negative patients) were collected. Each specimen was analyzed through smear examination and culture. All nucleic acid amplification testing results were included. Analyses looked at the incremental yield of positive cases of each successive specimen collection, and time to diagnosis. A total of 354 patients had at least one positive culture. Sputum allowed a diagnosis in 92% of cases (including a gain in sensitivity of around 7% for the third sputum specimen), with 160 smear-positive patients (45%). Among smear-negative patients, 109 underwent a fibroscopy procedure (culture sensitivity of 75%), and 59 had a post-fibroscopy specimen collected, which together identified the rest of the patients (8%). Molecular testing was used in 237 specimens. Median time to diagnosis was 11 days, which was significantly reduced among smear-negative patients when molecular testing was used (P<0.001). Shortening the delay between sputum specimen collections did not alter procedure sensitivity. We identified several aspects of the French tuberculosis diagnosis algorithm that could be improved, and posed the basis for a prospective study. Centers in higher incidence areas could benefit from a dedicated, predefined procedure exploring suspicions of tuberculosis. A high suspicion score of tuberculosis could drive the reasoned use of molecular testing in such settings.

Identifiants

pubmed: 33069842
pii: S0399-077X(20)30734-4
doi: 10.1016/j.medmal.2020.10.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-278

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

S B Gressens (SB)

Service des maladies infectieuses et tropicales, Hôpital Avicenne, 93017 Bobigny, France.

T Billard-Pomares (T)

Service de microbiologie clinique, Hôpital Avicenne, 93017 Bobigny, France; Université Paris 13, IAME, Inserm, 93017 Bobigny, France.

H Leboité (H)

Université Paris 5, Paris-Descartes, 12, rue de l'École de Médecine, 75006 Paris, France.

P Cruaud (P)

Service de microbiologie clinique, Hôpital Avicenne, 93017 Bobigny, France.

O Bouchaud (O)

Service des maladies infectieuses et tropicales, Hôpital Avicenne, 93017 Bobigny, France.

E Carbonnelle (E)

Service de microbiologie clinique, Hôpital Avicenne, 93017 Bobigny, France; Université Paris 13, IAME, Inserm, 93017 Bobigny, France.

F Méchaï (F)

Service des maladies infectieuses et tropicales, Hôpital Avicenne, 93017 Bobigny, France; Université Paris 13, IAME, Inserm, 93017 Bobigny, France. Electronic address: frederic.mechai@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH